SEC 13F Intelligence

Managers / Q4 2018 · view latest →

Ghost Tree Capital, LLC

CIK 0001595851 · 667 MADISON AVENUE, 5TH FLOOR, SUITE 12, NEW YORK, NY, 10065 · 6467790120

Reported Value
$285M
Q4 2018
Positions
39
Filings on Record
32
2019–present window
Filed
Feb 14, 2019
original filing

Summary

Ghost Tree Capital, LLC reported $285M in U.S.-listed holdings across 39 positions for Q4 2018.

Its largest position, MRTXEUR, represents 6.0% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+39.1%
share of reported value
Largest Position
+6.0%
Mirati Therapeutics

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $285MQ4 ’18Q1 ’19: $369MQ2 ’19: $477MQ3 ’19: $394MQ3 ’19Q4 ’19: $529MQ1 ’20: $377MQ2 ’20: $379MQ2 ’20Q3 ’20: $346MQ4 ’20: $449MQ1 ’21: $425MQ1 ’21Q2 ’21: $364MQ3 ’21: $342MQ4 ’21: $279MQ4 ’21Q1 ’22: $461MQ2 ’22: $192MQ3 ’22: $356MQ3 ’22Q4 ’22: $234MQ1 ’23: $338MQ2 ’23: $303MQ2 ’23Q3 ’23: $304MQ4 ’23: $306MQ1 ’24: $361MQ1 ’24Q2 ’24: $319MQ3 ’24: $331Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 63.2%ETP: 24.7%Other: 10.5%ADR: 1.7%
  • Common Stock · 63.2% · $180M
  • ETP · 24.7% · $70M
  • Other · 10.5% · $30M
  • ADR · 1.7% · $5M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
SPDR SERIES TRUSTNEW+750.0K750.0K+$65M$65M
IMMUIMMUNOMEDICS INCNEW+1.60M1.60M+$21M$21M
MRTXEURMIRATI THERAPEUTICS INCNEW+400.0K400.0K+$17M$17M
DRNAUSDDICERNA PHARMACEUTICALS INCNEW+1.25M1.25M+$13M$13M
VRTXVERTEX PHARMACEUTICALS INCNEW+80.0K80.0K+$13M$13M
RTRXEURRETROPHIN INCNEW+500.0K500.0K+$11M$11M
BIOHAVEN PHARMACTL HLDG CO LNEW+275.0K275.0K+$10M$10M
ANABANAPTYSBIO INCNEW+140.0K140.0K+$9M$9M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

34 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1MRTXEURMIRATI THERAPEUTICS INChistory →COM5.95%$17M400.0K
2DRNAUSDDICERNA PHARMACEUTICALS INChistory →COM4.69%$13M1.25M
3VRTXVERTEX PHARMACEUTICALS INChistory →COM4.65%$13M80.0K
4IMMUIMMUNOMEDICS INChistory →COM4.00%$11M800.0K
5RTRXEURRETROPHIN INChistory →COM3.97%$11M500.0K
6BIOHAVEN PHARMACTL HLDG CO LCOM3.57%$10M275.0K
7ANABANAPTYSBIO INChistory →COM3.13%$9M140.0K
8RCKTROCKET PHARMACEUTICALS INChistory →COM3.12%$9M600.0K
9IOVAIOVANCE BIOTHERAPEUTICS INChistory →COM3.10%$9M1.00M
104XC1KALVISTA PHARMACEUTICALS INChistory →COM2.94%$8M425.0K
11ASCENDIS PHARMA A SSPONSORED ADR2.75%$8M125.0K
12SRPTSAREPTA THERAPEUTICS INChistory →COM2.68%$8M70.0K
13OBSEVA SACOM2.44%$7M550.0K
14BOLDEURAUDENTES THERAPEUTICS INChistory →COM2.24%$6M300.0K
15AM6AMICUS THERAPEUTICS INChistory →COM2.18%$6M650.0K
161T7TRICIDA INChistory →COM2.07%$6M250.0K
17FXFINVESCO CURNCYSHS SWISS FRANhistory →SWISS FRANC1.84%$5M55.2K
18ORTXUSDORCHARD THERAPEUTICS PLChistory →ADS1.66%$5M300.0K
19VRAYQVIEWRAY INChistory →COM1.60%$5M750.0K
20KDMNKADMON HLDGS INChistory →COM1.46%$4M2.00M
21GBTUSDGLOBAL BLOOD THERAPEUTICS INhistory →COM1.44%$4M100.0K
22BCRXBIOCRYST PHARMACEUTICALShistory →COM1.42%$4M500.0K
23ZFGNUSDZAFGEN INChistory →COM1.30%$4M750.0K
24BIODELIVERY SCIENCES INTL INCOM1.30%$4M1.00M
25MNTAMOMENTA PHARMACEUTICALS INChistory →COM1.26%$4M325.0K
26ALNYALNYLAM PHARMACEUTICALS INCCOM0.90%$3M35.0K
27ARVNARVINAS INCCOM0.79%$2M175.0K
28ACADACADIA PHARMACEUTICALS INCCOM0.71%$2M125.0K
29UROVANT SCIENCES LTDSHS0.69%$2M300.0K
30CATALYST BIOSCIENCES INCCOM NEW0.55%$2M200.0K
31GENOCEA BIOSCIENCES INCCOM0.35%$1M3.52M
32PTIEURPROTEOSTASIS THERAPEUTICS INCOM0.22%$616,000190.0K
33SG7SAGE THERAPEUTICS INCCOM0.11%$316,0003.3K
34MOTUS GI HLDGS INCCOM0.11%$311,000100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$331M54Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$319M63Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$361M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$306M52Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$304M70Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$303M57Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$338M58May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$234M35Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$356M44Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$192M34Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$461M42May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$279M47Feb 16, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M60Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M52Aug 11, 202113F-HRchanges · EDGAR ↗
Q1 2021$425M50May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$449M43Feb 18, 2021RESTATEMENTchanges · EDGAR ↗
Q3 2020$346M47Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$379M43Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$377M49May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$529M53Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$394M44Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$477M43Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$369M39May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$285M39Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.